Ether (ETH) was priced at $2,420.16 on October 18, staying within the forecasted October range of $2,300 to $2,650. The price was below its 50-day and 20-day moving averages, which were $2,494.60 and $2,549.40 respectively as of October 15. The 14-day relative strength index stood at 39.69, indicating moderate momentum. This positioning suggests Ether is consolidating within expected levels, with potential movement influenced by these technical indicators.
Ether trading at $2,420.16 provides context for this report on October 18. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 19, 2026 14:01 WIB: out of 50 major cryptocurrencies, 36 rose and 13 fell today. Notable movers include CAKE at Rp39,865 with a 1-day change of +2.41% and a typical hold time of 75 days, ENJ at Rp490 down 2.36%, and MANA at Rp1,529 down 2.30%, with respective Pluang order activities showing mostly sell-side interest except MANA which had a slight buy majority.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
